Logan Health Research

Kalispell, Montana 59901

1 studies enrolling now · 13 studies all time

What they study most

Acute Myocardial Infarction, Adenoma, Cancer, Cardiomyopathies, Cardiovascular Diseases, Chronic Kidney Disease, Colon Cancer, Colon Diseases, Colon Lesion, Colon Neoplasm, Colon Polyp, Colorectal Cancer

Studies at this site

• Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer — Recruiting now
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight — Completed
• A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk — Completed
• Prevention of Colorectal Cancer Through Multiomics Blood Testing — Completed
• A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin — Completed
• Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% — Completed
• The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening — Completed
• Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy — Completed
• Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight — Completed
• A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
• Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack — Completed